Abstract
Background: Among patients with COVID-19 admitted to a hospital, emerging data suggest that hypertension may be associated with an increased risk of mortality due to COVID-19. Angiotensin II receptor blockers (ARB) is one of the first-line medica�tions for the management of a large proportion of patients with hypertension. Recent studies showed that ARB was associated with a significant lower risk of hospitalization in COVID-19 patients with hypertension. This study aimed to investigate the impact of ARB
on mortality risk in covid-19 patients.
Subjek dan Metode: A systematic review and meta-analysis was conducted following PICO method, i.e Population: COVID-19 patients with hypertension, Intervention: Angiotensin Receptor Blockers (ARB) therapy, Comparison: non ARB therapy, and Outcome: mortality. Cohort studies published from 2020 to 2022 was collected from Science Direct, PubMed, and Google Scholar databases. English or Indonesian full-text articles which reported odds ratio were involved for screening process. The articles selected using PRISMA flow chart and the data were quantitatively assessed using Review Manager 5.4 application.
Results: 5 cohort studies involved 4,604 COVID-19 patients from United States, China, and United Kingdom were selected for meta-analysis. This study showed that covid-19 patients with hypertension comorbidity who received ARB therapy had lower risk to mortality compared to those without ARB therapy (OR= 0.82; 95% CI= 0.68 to 1.00; p= 0.050).
Conclusion: Mortality risk in COVID-19 patients with hypertension comorbidity reduces with Angiotensin Receptor Blockers (ARB) therapy.
Article Data
